top of page
Inspired by Passion
Developing Therapies to
Transform
the Practice of Medicine
ABOUT US
Triursus Therapeutics is a cutting edge biotechnology company, spun out of technology and insights developed in Dr. Everett Meyer’s Lab at Stanford University in conjunction with our other world-class founders Rosemarie DeKruyff, Ph.D. and Gordon Freeman, Ph.D.
We’re developing novel monoclonal antibodies against several targets for the potential treatment of serious inflammatory diseases such as inflammatory bowel disease (IBD: Crohn disease and ulcerative colitis), graft-versus-host disease (GVHD), and others.
OUR VISION
practice_areas
OUR VISION
OUR LEAD INDICATION UNDER DEVELOPMENT:
GVHD: GRAFT-VERSUS-HOST DISEASE
We want to change the way transplant medicine is practiced, by transforming the way patients with serious hematologic malignancies are treated. Despite the best current care, many patients undergoing a potentially curative transplant develop GVHD. GVHD has a high rate of morbidity and mortality. Because of this high unmet need, we founded Triursus Therapeutics to develop potential therapies for GVHD.
Let doctors and patients focus on curing cancer, not battling GVHD
OTHER INDICATIONS UNDER DEVELOPMENT:
INFLAMMATORY BOWEL DISEASE (IBD) AND
OTHER DISEASES OF INFLAMMATION
We’re leveraging our unique insights on disease biology and pathophysiology to develop potential therapeutics to address other areas of high unmet need related to serious diseases of inflammation, including Crohn disease, ulcerative colitis, and other conditions.
our_vision
Looking for a Career
LOOKING FOR A CAREER?
We are a team of passionate people that are visionaries with a sharp focus on the details. If you are interesting in learning more about how we are making a difference, please contact us.
OUR TEAM
FOUNDERS and ADVISORS
Everett Meyer, M.D., Ph.D.
(Founder, BOD)
Medical & Scientific Director
Bone Marrow Transplantation,
Stanford University
Rosemarie DeKruyff, Ph.D.
(Founder, Advisor, BOD)
Professor, Stanford University
Advisor Sean Parker Inst.
Gordon Freeman, Ph.D. (Founder, Advisor)
Professor, Harvard University
Dana-Farber Cancer Institute
Kirk Essenmacher, M.D., M.B.A. (CEO Triursus Therapeutics)
Genentech, Alvine Pharmaceuticals, Abbott, Guidant Corporation
.jpeg)
Hua Tu, Ph.D.
(Collaborator, BOD)
CEO, LakePharma
John “Lippy” Lippincott, Ph.D.
(Collaborator)
VP, AlivaMab Discovery Services
Want to learn more about our therapeutic focus? Please fill in the following contact form:
contact
CONTACT
Triursus Therapeutics
(born in Palo Alto)
bottom of page